Compare ELOG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELOG | NEUP |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 21.7M |
| IPO Year | 2025 | N/A |
| Metric | ELOG | NEUP |
|---|---|---|
| Price | $1.08 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 121.8K | 31.1K |
| Earning Date | 02-27-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.27 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $45,962,309.00 | $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.97 | ★ N/A |
| Revenue Growth | ★ 10.64 | N/A |
| 52 Week Low | $0.85 | $3.65 |
| 52 Week High | $3.60 | $21.40 |
| Indicator | ELOG | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 45.72 |
| Support Level | $0.85 | $3.94 |
| Resistance Level | $1.13 | $4.07 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 43.60 | 25.49 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.